Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Citius Pharmaceuticals, Inc. CTXR announced that it has acquired the exclusive in-license rights of Dr. Reddy’s Laboratories RDY for E7777 (denileukin diftitox). The candidate is an improved ...

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

Citius Pharmaceuticals is a late-stage biotech with a drug to treat lymphoma, but their cash runway is not long enough for FDA approval. Their flagship drug, Lymphir, has shown promising results in a ...

We feel now is a pretty good time to analyse Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) business as it appears the company may be on the cusp of a considerable accomplishment. Citius Pharmaceuticals ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...